Wedbush raised the firm’s price target on Praxis Precision to $48 from $40 and keeps a Neutral rating on the shares. The firm notes the company disclosed an interim analysis in the Essential3 Study 1. The assessment will include a sample size re-estimation. Given the challenges associated with recent ET studies and limited prospective data surrounding the mADL primary endpoint it would appear prudent, Wedbush says. Following the update, the firm is making minor adjustments to its estimates. Wedbush remains cautious on the ET opportunity.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision Medicines Unveils Updated Corporate Presentation
- Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results
- Praxis Precision reports Q2 EPS ($1.74), consensus ($2.31)
- Is PRAX a Buy, Before Earnings?
- Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue